Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04608409 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
A Phase 1 study of Ovarian Cancer, sponsored by Frederick R. Ueland, M.D..
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT04608409: Completed Phase 1 study of Ovarian Cancer, sponsored by Frederick R. Ueland, M.D..
NCT04608409 is a Phase 1 study of Ovarian Cancer that has completed, run by Frederick R. Ueland, M.D.. The registered enrollment target is 16 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04608409, a Phase 1 study of Ovarian Cancer, has completed, sponsored by Frederick R. Ueland, M.D..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will be a phase I dose-escalation study of lapatinib and paclitaxel for platinum-resistant ovarian cancer, which will establish the phase II dose for subsequent efficacy trials.
Primary Outcome
Number of patients with progression-free survival at one year.
Conditions Studied
Interventions
- DRUG Lapatinib and Paclitaxel
Study Locations (1)
Kentucky
- Markey Cancer Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2024-05-17 |
| Phase | Phase 1 |
What the finished NCT04608409 record still lists
NCT04608409 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Lapatinib and Paclitaxel is the first listed.
NCT04608409 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT04608409 about?
NCT04608409 is a clinical study titled "Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer". This trial will be a phase I dose-escalation study of lapatinib and paclitaxel for platinum-resistant ovarian cancer, which will establish the phase II dose for subsequent efficacy trials.
What is the current status of trial NCT04608409?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-03-17. Estimated completion is 2024-05-17.
What conditions does trial NCT04608409 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT04608409?
The interventions under investigation include: Lapatinib and Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT04608409?
This trial is sponsored by Frederick R. Ueland, M.D., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04608409 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04608409's enrollment target sits among peer trials
16 299th of 322 higher than 23 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI